Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Pozycja w akcjach #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Cena akcji
$17.64
Kapitalizacja rynkowa
$32.65B
Zmiana (1 dzień)
-3.24%
Zmiana (1 rok)
-23.70%
Kraj
JP
Handel Daiichi Sankyo Company, Limited (DSNKY)

Kategoria

Zyski dla Daiichi Sankyo Company, Limited (DSNKY)
Zyski w Dec 2025 TTM: $2.25B
Według najnowszych raportów finansowych Daiichi Sankyo Company, Limited, obecny zysk firmy wynosi $2.25B. W roku 2024 firma osiągnęła zysk w wysokości $1.57B, wzrost w porównaniu do zysku z roku 2023, który wynosił $955.41M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Daiichi Sankyo Company, Limited od 2000 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $2.25B -5.02%
2025 $2.37B 51.37%
2024 $1.57B 64.05%
2023 $955.41M 58.24%
2022 $603.78M -9.78%
2021 $669.24M -49.03%
2020 $1.31B 69.80%
2019 $773.25M 1.40%
2018 $762.56M -3.25%
2017 $788.16M -27.54%
2016 $1.09B 63.21%
2015 $666.47M -31.10%
2014 $967.36M -1.02%
2013 $977.31M 139.07%
2012 $408.79M -71.86%
2011 $1.45B 39.41%
2010 $1.04B -133.26%
2009 $-3.13B -287.21%
2008 $1.67B 55.54%
2007 $1.08B -7.55%
2006 $1.16B 60.36%
2005 $725.65M -8.51%
2004 $793.11M 29.61%
2003 $611.93M 0.45%
2002 $609.17M -8.18%
2001 $663.43M -26.55%
2000 $903.21M 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$25.73B 1,041.79%
US
$12.40B 450.35%
GB
$32.58B 1,345.82%
US
$6.60B 192.75%
US
$16.35B 625.63%
CH